Usoro ọgwụgwọ CAR-T maka ọrịa kansa afọ

Claudin18.2 (CLDN18.2) bụ protein njikọ siri ike nke a na-egosipụta kpọmkwem na epithelium gastric na nke ukwuu n'elu sel cancer gastric. CT041 (koodu mmepe CG4006) bụ ngwaahịa CAR-T na-ezubere iche maka CLDN18.2. Data nkebi nke mbụ na-egosi ọrụ mgbochi tumor na-ekwe nkwa n'ime nnukwu ọgwụgwọ, CLDN18.2 na-arịa ọrịa cancer gastric dị mma.

A na-ahụkwa oke okwu HER2 na mpaghara ndị ọrịa kansa afọ. Usoro ọgwụgwọ CAR-T HER2 ezubere iche egosila ikike mgbochi tumor na ọmụmụ izizi na mmalite ụlọ ọgwụ. Triumvira Immunologics'TAC01-HER2 dị ugbu a na ule ụlọ ọgwụ na-agba nke Abụọ.

• Ezubere iche nke ukwuu: Site n'ịduzi mkpụrụ ndụ CAR-T megide CLDN18.2 ma ọ bụ HER2, mkpụrụ ndụ ọrịa kansa afọ nwere ike mata nke ọma ma kpochapụ ya, na-ebelata mmetụta nke tumor.

• Imeri Mgbochi Ọgwụgwọ Multiline: N'ime ule CT041, ndị otu ọrịa cancer afọ na-enweta nzaghachi ebumnobi (ORR) nke 57.1%, ọnụ ọgụgụ nchịkwa ọrịa (DCR) nke 75.0%, na nlanarị ọnwa 6 (OS) nke 81.2% na ndị ọrịa dara ọtụtụ usoro ọgwụgwọ tupu oge eruo.

• Azịza na-adịgide adịgide: Ọgwụgwọ CLDN18.2-CAR-T na-ewepụta oge nzaghachi nke ọnwa 6 nke 44.8%, na-atụ aro ike maka uru ahụike ogologo oge.

• Usoro ọgwụgwọ ahaziri onwe ya: Iji mkpụrụ ndụ T nke onye ọrịa na-ebelata ihe ize ndụ nke ịjụ ma kwalite nchekwa na nrụpụta ọrụ.

• Mkpokọta ọbara T-Cell
  A na-ekewa mkpụrụ ndụ T na mpụta ọbara onye ọrịa site na leukapheresis.

• Injinia mkpụrụ ndụ ihe nketa
  N'ime ụlọ nyocha GMP kwadoro, a na-atụgharị mkpụrụ ndụ T iji gosipụta CAR na-ezubere CLDN18.2 ma ọ bụ HER2, wee gbasaa ex vivo.

• Ihe na-edozi Lymphodepleting
  A na-enye usoro nkwadebe nke cyclophosphamide na fludarabine iji mebie lymphocytes endogenous ma mepụta niche dị mma maka mgbasawanye cell CAR-T.

• Mkpịsị mkpụrụ ndụ CAR-T
  A na-agbanyeghachi mkpụrụ ndụ CAR-T ndị arụrụ arụ azụ n'ime onye ọrịa n'ime eriri afọ.

• Nleba anya na njikwa
  Mgbe infusion gasịrị, a na-enyocha ndị ọrịa nke ọma maka ọrịa cytokine release syndrome (CRS) na neurotoxicity, yana ntinye oge dị ka ọ dị mkpa.

• CT041 (CLDN18.2-CAR-T) Usoro nke nwa oge nyocha
  N'ime ndị ọrịa 37 a na-agwọta nke ukwuu, otu subgroup ọrịa kansa afọ nwetara ORR 57.1%, DCR 75.0%; 94.6% nwetara naanị ọkwa 1-2 CRS, na-enweghị ọkwa 3 ma ọ bụ karịa CRS ma ọ bụ neurotoxicity; Ogologo oge nzaghachi nke ọnwa 6 bụ 44.8%.

• Satri-cel (na-ezubere CLDN18.2) Nsonaazụ ikpeazụ nke agba nke mbụ
  N'ime 98 CLDN18.2-ezigbo ọrịa cancer eriri afọ, ORR bụ 38.8%, DCR 91.8%; Ịlanarị na-enweghị ọganihu nke etiti (mPFS) bụ ọnwa 4.4 (95% CI 3.7-6.6), nlanarị n'ozuzu (mOS) ọnwa 8.8 (95% CI 7.1-10.2); 96.9% nwetara naanị ọkwa 1–2 CRS, na-enweghị ọkwa 3+ CRS ma ọ bụ ọnwụ metụtara ya.

• HER2-CAR-T Data Clinical mbụ
  Ihe omumu nke mbu n'ime mmadu gosiputara profaịlụ nchekwa enwere ike ijikwa; a na-aga n'ihu na ikpe ndebanye aha n'ọkwa nke Abụọ.

• Nkà na ụzụ na-edu ndú
  BIOOCUS na-arụ ọrụ ụlọ nrụpụta mkpụrụ ndụ GMP-ọkwa mba ofesi, na-ahụ maka mmepụta cell CAR-T nke ọma na nke na-agbanwe agbanwe.

• Otu ọkachamara ọkachamara multidisciplinary
  Ndị otu anyị gụnyere ndị ọkachamara nwere ahụmahụ na immunology, oncology, na ọgwụgwọ cell, na-ebuga njikwa ahaziri nke ọma.

• Ahụmahụ ụlọ ọgwụ mba ụwa
  Anyị agwọla ndị ọrịa si gburugburu ụwa, na-achịkọta nnukwu nchekwa na data arụmọrụ.

• Ọrụ ngwụcha ruo ngwụcha zuru oke
  Site na nhazi protocol na nhazi ọgwụgwọ esenidụt ruo ogologo oge na-esochi infusion, BIOOCUS na-enye nkwado otu nkwụsị.